RNARevive
ActiveRNARevive is developing a next-generation RNA platform that enables long-lasting, low-dose protein therapeutics. Our lead candidates tackle the anti-aging and longevity space, targeting osteoporosis, age-related macular degeneration (AMD), and liver diseases.
What it does
RNArevive Therapeutics is a biotechnology company specializing in the development of a next-generation self-amplifying RNA (saRNA) platform designed to enable durable, low-dose protein therapeutics in vivo. This innovative technology addresses key challenges of traditional biologics and mRNA therapies, such as limited durability, high manufacturing costs, and frequent dosing requirements. The platform is applied across chronic and specialty disease areas, including bone health, ophthalmology, and liver diseases, aiming to reduce patient and healthcare system burdens through long-lasting protein expression. By integrating advanced RNA engineering with scalable manufacturing and delivery solutions, RNArevive Therapeutics contributes to the advancement of RNA-based medicines. Collaborative efforts with academic and industry partners support the development of a versatile platform capable of addressing multiple therapeutic indications, positioning the company as an important innovator in the life sciences sector.